Literature DB >> 30622878

Discovery of Novel Molecular Frameworks of Farnesoid X Receptor Modulators by Ensemble Machine Learning.

Daniel Merk1, Francesca Grisoni1,2, Kay Schaller1, Lukas Friedrich1, Gisbert Schneider1.   

Abstract

The bile acid activated transcription factor farnesoid X receptor (FXR) has revealed therapeutic potential as a molecular drug target for the treatment of hepatic and metabolic disorders. Despite strong efforts in FXR ligand development, the structural diversity among the known FXR modulators is limited. Only four molecular frameworks account for more than 50 % of the FXR modulators annotated in ChEMBL. Here, we leverage machine learning methods to expand the chemical space of FXR-targeting small molecules by employing an ensemble of three complementary machine learning approaches. A counter-propagation artificial neural network, a k-nearest neighbor learner, and a three-dimensional pharmacophore descriptor were combined to retrieve novel FXR ligands from a collection of more than 3 million compounds. The ensemble machine learning model identified six new FXR modulators among ten top-ranked candidates. These active hits comprise both FXR activators and antagonists with micromolar potencies. With four novel FXR ligand scaffolds, these computationally identified bioactive compounds appreciably expand the chemical space of known FXR modulators and may serve as starting points for hit-to-lead expansion.

Entities:  

Keywords:  drug design; drug discovery; neural networks; nuclear receptors; virtual screening

Year:  2018        PMID: 30622878      PMCID: PMC6317935          DOI: 10.1002/open.201800156

Source DB:  PubMed          Journal:  ChemistryOpen        ISSN: 2191-1363            Impact factor:   2.911


  26 in total

1.  "Scaffold-Hopping" by Topological Pharmacophore Search: A Contribution to Virtual Screening.

Authors: 
Journal:  Angew Chem Int Ed Engl       Date:  1999-10-04       Impact factor: 15.336

2.  Identification of a chemical tool for the orphan nuclear receptor FXR.

Authors:  P R Maloney; D J Parks; C D Haffner; A M Fivush; G Chandra; K D Plunket; K L Creech; L B Moore; J G Wilson; M C Lewis; S A Jones; T M Willson
Journal:  J Med Chem       Date:  2000-08-10       Impact factor: 7.446

3.  Counterpropagation networks.

Authors:  R Hecht-Nielsen
Journal:  Appl Opt       Date:  1987-12-01       Impact factor: 1.980

4.  Virtual computational chemistry laboratory--design and description.

Authors:  Igor V Tetko; Johann Gasteiger; Roberto Todeschini; Andrea Mauri; David Livingstone; Peter Ertl; Vladimir A Palyulin; Eugene V Radchenko; Nikolay S Zefirov; Alexander S Makarenko; Vsevolod Yu Tanchuk; Volodymyr V Prokopenko
Journal:  J Comput Aided Mol Des       Date:  2005-06       Impact factor: 3.686

5.  Scaffold hopping by "fuzzy" pharmacophores and its application to RNA targets.

Authors:  Yusuf Tanrikulu; Manuel Nietert; Ute Scheffer; Ewgenij Proschak; Kristina Grabowski; Petra Schneider; Markus Weidlich; Michael Karas; Michael Göbel; Gisbert Schneider
Journal:  Chembiochem       Date:  2007-11-05       Impact factor: 3.164

6.  Evaluating virtual screening methods: good and bad metrics for the "early recognition" problem.

Authors:  Jean-François Truchon; Christopher I Bayly
Journal:  J Chem Inf Model       Date:  2007-02-09       Impact factor: 4.956

7.  Discovery of XL335 (WAY-362450), a highly potent, selective, and orally active agonist of the farnesoid X receptor (FXR).

Authors:  Brenton Flatt; Richard Martin; Tie-Lin Wang; Paige Mahaney; Brett Murphy; Xiao-Hui Gu; Paul Foster; Jiali Li; Parinaz Pircher; Mary Petrowski; Ira Schulman; Stefan Westin; Jay Wrobel; Grace Yan; Eric Bischoff; Chris Daige; Raju Mohan
Journal:  J Med Chem       Date:  2009-02-26       Impact factor: 7.446

8.  6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.

Authors:  Roberto Pellicciari; Stefano Fiorucci; Emidio Camaioni; Carlo Clerici; Gabriele Costantino; Patrick R Maloney; Antonio Morelli; Derek J Parks; Timothy M Willson
Journal:  J Med Chem       Date:  2002-08-15       Impact factor: 7.446

9.  Identification of an N-oxide pyridine GW4064 analog as a potent FXR agonist.

Authors:  Song Feng; Minmin Yang; Zhenshan Zhang; Zhanguo Wang; Di Hong; Hans Richter; Gregory Martin Benson; Konrad Bleicher; Uwe Grether; Rainer E Martin; Jean-Marc Plancher; Bernd Kuhn; Markus Georg Rudolph; Li Chen
Journal:  Bioorg Med Chem Lett       Date:  2009-03-09       Impact factor: 2.823

10.  Identification of a potent synthetic FXR agonist with an unexpected mode of binding and activation.

Authors:  Stephen M Soisson; Gopalakrishnan Parthasarathy; Alan D Adams; Soumya Sahoo; Ayesha Sitlani; Carl Sparrow; Jisong Cui; Joseph W Becker
Journal:  Proc Natl Acad Sci U S A       Date:  2008-04-07       Impact factor: 11.205

View more
  1 in total

Review 1.  Review of in silico studies dedicated to the nuclear receptor family: Therapeutic prospects and toxicological concerns.

Authors:  Asma Sellami; Manon Réau; Matthieu Montes; Nathalie Lagarde
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-13       Impact factor: 6.055

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.